Modern possibilities of treatment of inflammatory diseases of the respiratory tract of viral etiology

Viral diseases of the respiratory tract are one of the most pressing health problems worldwide. Influenza viruses, parainfluenza, rhinoviruses, adenoviruses, herpes viruses, enteroviruses, ESNO and Coxsackie viruses, penetrating by airborne droplets and affecting mucous membranes, cause catarrhal inflammation at the sites of invasion, which is accompanied by rhinitis, pharyngitis, tonsillitis, laryngitis, tracheitis. Viruses determine a complex of immunological disorders leading to an imbalance of cellular and humoral immunity factors, a change in mucociliary clearance, which contributes to the chronic persistence of viruses and the attachment of bacterial infection. The authors consider the features of the clinical course of viral lesions of the respiratory tract, possible complications and approaches to the treatment of these conditions. In the absence of effective etiotropic treatment for most respiratory viral infections, the possibility of influencing the course of the disease by stimulating phagocytosis, T-lymphocytes, reducing the production of proinflammatory cytokines and increasing the level of immunoglobulins and interferons is of great importance. The authors discuss the prospects of using inosine pranobex, a synthetic purine derivative, as an immune–stimulating and non-specific antiviral agent in the treatment of inflammatory diseases of the respiratory tract caused by viral infection. The incidence of influenza and acute respiratory viral infections exhibits seasonal patterns, however in addition to sick contacts, the immune system status is also important, which explains the recurrence of viral infections in young children and adults with chronic somatic pathology accompanied by immunosuppression. At the same time, the physiological features of the early life immune system are primarily characterized by the insufficiency of cellular and humoral factors of local immunity. This circumstance takes on particular and important significance in the context of insufficient effectiveness of respiratory viral infections therapy with available antiviral and symptomatic drugs and allows to consider the prospects for using immunostimulating agents. The authors conclude that inosine pranobex is effective and safe in the treatment of a wide range of respiratory viral infections.

1. Fleming DM, Elliot AJ, Nguyen-van Tam JS. A Winter’s Tale: Coming to Terms With Winter Respiratory Illnesses. London, England: Health Protection Agency; 2005.

2. Weber O. The role of viruses in the etiology and pathogenesis of common cold. In: Eccles RWO (ed.). Common Cold. Basel, Switzerland: Birkhäuser Verlag; 2009.

3. Mousa HA. Prevention and Treatment of Influenza, Influenza-Like Illness, and Common Cold by Herbal, Complementary, and Natural Therapies. J Evid Based Complementary Altern Med. 2017;22(1):166–174. https://doi.org/10.1177/2156587216641831.

4. Ющук НД, Венгеров ЮЯ (ред.). Инфекционные болезни. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа; 2019. 1004 с.

5. Wark PAB, Ramsahai JM, Pathinayake P, Malik B, Bartlett NW. Respiratory Viruses and Asthma. Semin Respir Crit Care Med. 2018;39(1):45–55. https://doi.org/10.1055/s-0037-1617412.

6. Zaitsev AA, Sinopalnikov AI. Influenza: Diagnosis and Treatment. RMJ. 2008;(22):1494–1501. (In Russ.) Available at: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Gripp_diagnostika_i_lechenie.

7. Zaitsev AA, Akimkin VG, Tutelyan AV, Maryin GG. Topical Issues of Epidemiology, Pharmacotherapy, and Prevention of Acute Respiratory Viral Infections. RMJ. Medical Review. 2018;(11):53–57. (In Russ.) Available at: https://www.rmj.ru/articles/infektsionnye_bolezni/Aktualynye_voprosy_epidemiologii_farmakoterapii_i_profilaktiki_ostryh_respiratornyh_virusnyh_infekciy/.

8. Greenberg SB. Update on rhinovirus and coronavirus infections. Semin Respir Crit Care Med. 2011;32(4):433–446. https://doi.org/10.1055/s-0031-1283283.

9. Aitov KA. Clinical Pattern, Diagnosis and Treatment of Flu and ARVI. Meditsinskiy Sovet. 2015;(2):33–37. (In Russ.) https://doi.org/10.21518/2079-701X-2015-2-33-37.

10. Киселев ОИ, Цыбалова ЛМ, Покровский ВИ (ред.). Грипп: эпидемиология, диагностика, лечение, профилактика. М.: Медицинское информационное агентство; 2012. 496 с.

11. Малый ВП, Андрейчин МА (ред.). Грипп (сезонный, птичий, пандемический) и другие ОРВИ. М.: ГЭОТАР-Медиа; 2013. 320 с.

12. Бартлетт Дж. Инфекции дыхательных путей. М.: Бином; СПб.: Невский диалект; 2000. 192 с.

13. Карпухин ГИ, Карпухина ОГ. Диагностика, профилактика и лечение острых респираторных заболеваний. СПб.: Гиппократ; 2000. 180 с.

14. Avdeev SN. Severe Forms of Pandemic Influenza A/H1N1 2009. Atmosfera. Pulmonologiya i Allergologiya. 2010;(4):2–10. (In Russ.) Available at: http://www.atmosphere-ph.ru/modules/Magazines/articles/pulmo/ap_4_2010_02.pdf.

15. Casanova JL, Abel L. The human model: a genetic dissection of immunity to infection in natural conditions. Nat Rev Immunol. 2004;4(1):55–66. https://doi.org/10.1038/nri1264.

16. Demedts IK, Brusselle GG, Vermaelen KY, Pauwels RA. Identifi cation and characterization of human pulmonary dendritic cells. Am J Respir Cell Mol Biol. 2005;(32):177–178. https://doi.org/10.1165/rcmb.2004-0279OC.

17. Belova EG. Flu is a disease of all ages. Lechaschi Vrach. 2003;(10):73–75. (In Russ.) Available at: https://www.lvrach.ru/2003/10/4530863.

18. Деева ЭГ. Грипп. На пороге пандемии. М.: ГЭОТАР-Медиа; 2008. 208 с.

19. Исаков ВА, Туркин ВВ, Стернин ЮИ, Кнорринг ГЮ. Системная энзимотерапия в комплексном лечении больных гриппом и ОРЗ. СПб.; 2008. 80 с.

20. Karpishchenko SA, Fatalieva AF. Modern Concept of Acute Rhinosinusitis treatment. RMJ. Medical Review. 2019;9(II):93–96. (In Russ.) Available at: https://www. rmj.ru/articles/otorinolaringologiya/Sovremennaya_koncepciya_lecheniya_ostrogo_rinosinusita/.

21. Gurov AV. Swelling of the Mucous Membrane of the Upper Respiratory Tract. How to Deal with It? RMJ. 2009;(19):1254–1259. (In Russ.) Available at: https://www.rmj.ru/articles/otorinolaringologiya/Otek_slizistoy_obolochki_verhnih_dyhatelynyh_puteyKak_s_nim_borotysya/.

22. Keilman LJ. Seasonal Influenza (Flu). Nurs Clin North Am. 2019;54(2):227–243. https://doi.org/10.1016/j.cnur.2019.02.009.

23. Egorov VI, Savlevich EL. The Role of Innate Immunity in the Development of Chronic Rhinosinusitis and Perspectives of Its Conservative Management. Almanac of Clinical Medicine. 2016;44(7):850–856. (In Russ.) https://doi.org/10.18786/2072-0505-2016-44-7-850-856.

24. Львов ДК (ред.). Вирусы и вирусные инфекции человека и животных. М.: Медицинское информационное агентство; 2013. 1200 с.

25. Amlaev KP. Influenza: Epidemiological, Diagnostic, Clinical, Therapeutic Aspects and Prevention. Vrach. 2020;(11):10–14. (In Russ.) https://doi.org/10.29296/25877305-2020-11-02.

26. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral Pneumonia. Lancet. 2011;377(9773):1264–1275. https://doi.org/10.1016/S0140-6736(10)61459-6.

27. Pawełczyk M, Kowalski ML. The Role of Human Parainfluenza Virus Infections in the Immunopathology of the Respiratory Tract. Curr Allergy Asthma Rep. 2017;17(3):16. https://doi.org/10.1007/s11882-017-0685-2.

28. Vandini S, Biagi C, Fischer M, Lanari M. Impact of Rhinovirus Infections in Children. Viruses. 2019;11(6):521. https://doi.org/10.3390/v11060521.

29. Turunen R, Koistinen A, Vuorinen T, Arku B, Söderlund-Venermo M, Ruuskanen O, Jartti T. The first wheezing episode: Respiratory virus etiology, atopic characteristics, and illness severity. Pediatr Allergy Immunol. 2014;25(8):796–803. https://doi.org/10.1111/pai.12318.

30. Kotaniemi-Syrjänen A, Reijonen TM, Korhonen K, Waris M, Vainionpää R, Korppi M. Wheezing due to rhinovirus infection in infancy: Bronchial hyperresponsiveness at school age. Pediatr Int. 2008;50(4):506–510. https://doi.org/10.1111/j.1442-200X.2008.02620.x.

31. Dunmire SK, Verghese PS, Balfour HHJr. Primary Epstein-Barr virus infection. J Clin Virol. 2018;102:84–92. https://doi.org/10.1016/j.jcv.2018.03.001.

32. Kryukov AI, Bessarab TP, Tsarapkin GYu, Tovmasian AS, Kishinevskii AYe, Agaev AG. Infectious mononucleosis in practice of otorhinolaryngologist. Vestnik Oto-Rino-Laringologii. 2021;86(4):79–85. (In Russ.) https://doi.org/10.17116/otorino20218604179.

33. Fugl A, Andersen CL. Epstein-Barr virus and its association with disease – a review of relevance to general practice. BMC Fam Pract. 2019;20(1):62. https://doi.org/10.1186/s12875-019-0954-3.

34. Shabrov AV, Gorbacheva IA, Fominykh YuA, Sycheva YuA, Donskaya OS, Kulikova YuR et al. Herpetic infection in otorhinolaryngology as a multimorbidity factor. Rossiiskaya Otorinolaringologiya. 2021;20(2):65–77. (In Russ.) https://doi.org/10.18692/1810-4800-2021-2-65-77.

35. Dioverti MV, Razonable RR. Cytomegalovirus. Microbiol Spectr. 2016;4(4). https://doi.org/10.1128/microbiolspec.DMIH2-0022-2015.

36. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001;344(18):1366–1371. https://doi.org/10.1056/NEJM200105033441804.

37. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3–20. https://doi.org/10.1038/s41580-021-00418-x.

38. Herrod HG. Follow-up of pediatric patients with recurrent infection and mild serologic immune abnormalities. Ann Allergy Asthma Immunol. 1997;79(5):460–464. https://doi.org/10.1016/S1081-1206(10)63044-X.

39. Drozdov VN, Vorob’eva OA, Serebrova SY, Shikh EV. Use of inosine pranobex in frequently ill children. Meditsinskiy Sovet. 2019;(17):186–191. (In Russ.) https://doi.org/10.21518/2079-701X-2019-17-186-191.

40. Kolosova NG. Acute respiratory infections in frequently ill children: rational etiotropic therapy. RMJ. 2014;22(3):204–207. (In Russ.) Available at: https://www.rmj.ru/articles/obshchie-stati/Ostrye_respiratornye_infekcii_u_chasto_boleyuschih_detey_racionalynaya_etiotropnaya_terapiya.

41. Khaitov RM, Pinegin BV. Immunomodulators: classification, pharmacological action, clinical application. Farmateka. 2004;(7):10–15. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/5343.

42. Akulich NF, Krivenko NA, Khnykov AM, Semenova VM, Dmitrachenko TI. Experience of using Groprinosin in the treatment of socially significant viral infections. Meditsinskie Novosti. 2009;(6):51–53. ( In Russ.) Available at: https://www.mednovosti.by/Journal.aspx?id=220.

43. Sergienko EN, Shmeleva NP, Germanenko IG, Gribkova NV. Influenza in children: clinical and epidemiological features and new treatment options. Meditsinskie Novosti. 2009;(14):1–4. ( In Russ.) Available at: https://www.mednovosti.by/Journal.aspx?id=230.

44. Savenkova MS, Isaeva EI, Vetrova EN, Kraseva GN, Abramova NA, Shabad MB et al. Role of antiviral therapy in respiratory infections in children: analysis of clinical and laboratory observations. Clinical Practice in Pediatrics. 2022;17(6):45–54. (In Russ.) https://doi.org/10.20953/1817-7646-2022-6-45-54.

45. Ruzhentsova TA, Garbuzov AA, Meshkova NA, Polova RV, Slyusar OI. The influence of antiviral therapy on the course of acute respiratory viral infections in children in modern conditions of breast cancer. Russian Journal of Woman and Child Health. 2024:7(2):163–170. (In Russ.) https://doi.org/10.32364/2618-8430-2024-7-2-12.

46. Simovanyan EN, Denisenko VB, Grigoryan AV, Kim MA, Bovtalo LF, Belugina LV. Epstein-Barr Virus Infection in Children: Improving the Diagnosis and Treatment Program. Children Infections. 2016;15(1):15–24. (In Russ.) https://doi.org/10.22627/2072-8107-2016-15-1-15-24.

47. Khaliullina SV, Pokrovskaya EM, Mannanova EF. Efficacy of Groprinosin in complex therapy of pharyngeal tonsil hypertrophy and chronic adenoiditis in children. Clinical Practice in Pediatrics. 2024;19(2):128–134. (In Russ.) https://doi.org/10.20953/1817-7646-2024-2-128-134.